WILMINGTON – Incyte has received U.S. Food and Drug Administration approval for Jakafi XR, an extended-release formulation of ruxolitinib. The new tablet allows for once-daily dosing, transitioning from the twice-daily requirement of the immediate-release version.
The approval covers adult patients with intermediate- or high-risk myelofibrosis and adult patients with polycythemia vera who are intolerant of hydroxyurea or had an inadequate response to therapy. Additionally, the drug is approved for adult and pediatric patients aged 12 and older with acute graft-versus-host disease (GVHD) refractory to steroids, as well as chronic GVHD that failed to respond to one or two prior lines of therapy.
Jakafi, first cleared in 2011 as the first JAK1/JAK2 inhibitor for myelofibrosis, is already a standard-of-care therapy in these indications, prescribed to help reduce spleen size, control blood counts and alleviate symptom burden in patients with serious, often life‑limiting hematologic conditions.[[3]] The introduction of the extended-release version is a strategic expansion of the Incyte portfolio. By reducing the dosing frequency, the company aims to improve patient compliance and treatment tolerability-two factors closely watched by payers and regulators in chronic disease management-while maintaining market share within the competitive JAK inhibitor sector.[[1]]
The regulatory decision followed an open-label, randomly assigned, two-period, two-way crossover study presented at the 67th American Society of Hematology Annual Meeting & Exposition. The trial involved 169 healthy participants, a design intended to isolate pharmacokinetic performance of the new formulation rather than evaluate disease outcomes.
| Metric | Ruxolitinib IR (Twice Daily) | Ruxolitinib XR (Once Daily) |
|---|---|---|
| Dosage | 25 mg | 55 mg |
| Median time to Cmax,ss | 2.0 hours | 3.0 hours |
| Average half-life | 3.0 hours | 5.4 hours |
| Treatment-emergent adverse events | 20.2% | 11.8% |
Data confirmed that the once-daily XR formulation is bioequivalent to the twice-daily IR formulation at steady state. While the safety profiles remained comparable, the XR group reported a lower percentage of treatment-emergent adverse events, an outcome that could support payer and formulary decisions if replicated in real‑world use.
Corporate Strategy and Market Positioning
The development of Jakafi XR aligns with broader pharmaceutical industry trends of lifecycle management, where companies introduce improved delivery mechanisms to extend the commercial viability of core assets and respond to evolving regulatory expectations around adherence and real-world effectiveness. Ruxolitinib has established itself as a primary therapy for myelofibrosis and GVHD, and the move to a once-daily regimen addresses a known friction point in chronic disease management, particularly for patients on complex multi-drug regimens.
The approval, granted under the existing U.S. statutory framework that governs small‑molecule drug review and post‑marketing surveillance, enables Incyte to offer a “suitable alternative” to the immediate-release version, potentially facilitating easier integration into combination therapies and reducing the burden on patients. For hospitals and transplant centers, the option of an extended-release tablet may simplify scheduling of GVHD regimens, which often have to be synchronized with other immunosuppressive therapies and monitoring protocols.
“Ruxolitinib has made a significant impact for quality of life and improvement in survival for patients with myelofibrosis, and deep impact for polycythemia vera and GVHD,” said Ruben Mesa, MD, President, Advocate Health Cancer National Service Line, President, Atrium Health Levine Cancer, and Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center. “The new approval of the extended release is a meaningful advance for patients. The ability for patients to benefit from once daily dosing will further increase compliance, simplify use for patients, will further benefit the tolerability profile, and might yield advantages in future combination approaches.”
Jakafi XR became available for pharmacy orders on May 8, 2026. The product remains under the regulatory oversight of the FDA for its specified adult and pediatric indications, with prescribers expected to follow existing label guidance on dosing, hematologic monitoring and management of infection risk.
